Lilly ditches tabalumab after another Phase III trial fails
This article was originally published in Scrip
Lilly has thrown in the towel on development of its anti-BAFF product tabalumab after it disappointed in Phase III in a second indication, systemic lupus erythematosus (SLE). Its development in rheumatoid arthritis had previously been dropped at the Phase III stage (scripintelligence.com, 8 February 2013).
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.